Two Sigma Advisers’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Two Sigma Advisers’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-55,838	Closed	-$37K	–	2961
2022 Q1	$37K	Sell	55,838 -15,400	-22%	-$13.1K	﹤0.01%	2623
2021 Q4	$92K	Sell	71,238 -17,563	-20%	-$31.2K	﹤0.01%	2419
2021 Q3	$193K	Sell	88,801 -213,300	-71%	-$464K	﹤0.01%	2257
2021 Q2	$825K	Sell	302,101 -21,300	-7%	-$53K	﹤0.01%	1718
2021 Q1	$844K	Buy	+323,401	New	+$915K	﹤0.01%	1742
2020 Q4	–	Sell	-86,377	Closed	-$399K	–	2652
2020 Q3	$399K	Buy	+86,377	New	+$285K	﹤0.01%	1904
2018 Q2	–	Sell	-6,063	Closed	-$65K	–	2536
2018 Q1	$65K	Buy	+6,063	New	+$97.4K	﹤0.01%	2249
2017 Q4	–	Sell	-1,588	Closed	-$87K	–	2418
2017 Q3	$87K	Buy	1,588 +288	+22%	+$48.6K	﹤0.01%	2130
2017 Q2	$241K	Buy	+1,300	New	+$228K	﹤0.01%	2062

Other funds holding SIOX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TVWM

Tower View Wealth Management Shorewood, Wisconsin $195M AUM 29.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers's SIOX Position: Q2 2022 in Review

Two Sigma Advisers sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2022, closing a stake of 55,838 shares — an estimated $37K sold.

Two Sigma Advisers first reported a position in SIOX in Q2 2017 and held it in 9 quarters. The position peaked at $844K in Q1 2021. 41 funds tracked by Wall St. Rank hold SIOX as of Q2 2022.

Two Sigma Advisers reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Two Sigma Advisers sold 55,838 Sio Gene Therapies Inc. Common Stock shares in Q2 2022, an estimated $37K.
Two Sigma Advisers first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2017 and held it in 9 quarters.
Two Sigma Advisers's Sio Gene Therapies Inc. Common Stock position peaked at $844K in Q1 2021.
41 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2022.

Based on Two Sigma Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.